2-Cys-Prx Mimetic Compounds for Low-Toxicity Vascular Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vascular diseases and pulmonary arterial hypertension suffer from significant side effects and cytotoxicity, limiting their effectiveness and safety.
Innovation Solution
Development of bridged Epidithiodioxopiperazine-based compounds that mimic 2-Cys-peroxiredoxin (2-Cys-Prx) activity, offering reduced toxicity and enhanced pharmacological effects, including compounds represented by Chemical Formula 1 or 2 and their pharmaceutically acceptable salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytotoxic drugs are used to inhibit vascular smooth muscle cell proliferation, then hyperplasia of smooth muscle cells is suppressed, but toxicity causes death of not only smooth muscle cells but also endothelial cells
Solution Approach 1:
The patent changes the mechanism of action from cytotoxic to anti-proliferative by using compounds that inhibit smooth muscle cell proliferation through modulation of cell cycle regulation and growth factor signaling, thereby suppressing hyperplasia without killing cells. This parameter change in the drug mechanism resolves the contradiction by eliminating non-specific cytotoxicity while maintaining anti-hyperplastic efficacy.
Solution Approach 2:
The patent introduces intermediary substances such as statins, anti-platelet agents, and growth factor inhibitors that mediate the inhibition of smooth muscle cell proliferation indirectly through multiple signaling pathways. These intermediaries target specific proliferative mechanisms without causing direct cytotoxic damage to endothelial cells, thus resolving the toxicity problem while maintaining therapeutic effect.
2Stress or pressure
If general vasodilators are used for treatment of pulmonary arterial hypertension, then pulmonary artery pressure is reduced, but significant side effects occur and effectiveness is limited
Solution Approach 1:
The patent applies local quality by using compounds that specifically target pulmonary vascular smooth muscle cells and endothelial cells in the pulmonary circulation, rather than using general systemic vasodilators. The compounds exhibit selective activity in the pulmonary artery, reducing pressure locally without causing widespread side effects throughout the body, thus resolving the contradiction between pressure reduction and side effect profile.
3Reliability
If drugs are developed to selectively promote recovery of damaged endothelial cell layer, then endothelial recovery is enhanced, but such selective drugs do not currently exist with adequate therapeutic potential
Solution Approach 1:
The patent develops compounds with multi-functionality that simultaneously inhibit smooth muscle cell proliferation and promote endothelial cell recovery. The compounds exhibit dual biological activities through modulation of growth factor signaling, anti-oxidant effects, and direct stimulation of endothelial cell migration and proliferation. This universal approach resolves the contradiction by providing a single therapeutic agent that addresses both needs, accelerating drug development compared to requiring separate selective drugs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit vascular smooth muscle cell proliferation and promote endothelial cell recovery, reducing toxicity and improving treatment outcomes for vascular diseases and pulmonary arterial hypertension.
Implementation Method 1
compounds exhibiting 2-Cys-peroxiredoxin (2-Cys-Prx) peroxidase mimetic activity
Implementation Method 2
PrxII eliminates hydrogen peroxide produced by platelet-derived growth factor (PDGF) in vascular smooth muscle cells
Data Source
AI summary
The present disclosure provides compounds capable of exhibiting effects similar to those of 2-Cys-peroxyredoxin (2-Cys-Prx) in the body with excellent pharmacological effects and reduced side effects such as reduced cytotoxicity, and pharmaceutical uses thereof. The compounds of the present disclosure and their pharmaceutically acceptable salts are useful for the treatment or prevention of vascular diseases, particularly ischemic coronary artery disease, arteriosclerosis, vascular restenosis, or pulmonary arterial hypertension. The compounds of the present invention and their pharmaceutically acceptable salts are particularly useful for the treatment or prevention of pulmonary arterial hypertension. The invention also provides methods of preparing the compounds of the present disclosure.